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Abstract
Background: Antibody-based immuneotherapy has achieved some success for cancer. But the
main problem is that only a few tumor-associated antigens or therapeutic targets have been known
to us so far. It is essential to identify more immunogenic antigens (especially cellular membrane
markers) for tumor diagnosis and therapy.
Methods: The membrane proteins of lung adenocarcinoma cell line A549 were used to immunize
the BALB/c mice. A monoclonal antibody 4E7 (McAb4E7) was produced with hybridoma technique.
MTT cell proliferation assay was carried out to evaluate the inhibitory effect of McAb4E7 on A549
cells. Flow cytometric assay, immunohistochemistry, western blot and proteomic technologies
based on 2-DE and mass spectrometry were employed to detect and identify the corresponding
antigen of McAb4E7.
Results: The monoclonal antibody 4E7 (McAb4E7) specific against A549 cells was produced, which
exhibited inhibitory effect on the proliferation of A549 cells. By the proteomic technologies, we
identified that ATP synthase beta subunit (ATPB) was the corresponding antigen of McAb4E7.
Then, flow cytometric analysis demonstrated the localization of the targeting antigen of McAb4E7
was on the A549 cells surface. Furthermore, immunohistochemstry showed that the antigen of
McAb4E7 mainly aberrantly expressed in tumor cellular membrane in non-small cell lung cancer
(NSCLC), but not in small cell lung cancer (SCLC). The rate of ectopic expressed ATPB in the
cellular membrane in lung adenocarcinoma, squamous carcinoma and their adjacent nontumourous
lung tissues was 71.88%, 66.67% and 25.81% respectively.
Conclusion: In the present study, we identified that the ectopic ATPB in tumor cellular membrane
was the non-small cell lung cancer (NSCLC) associated antigen. ATPB may be a potential biomarker
and therapeutic target for the immunotherapy of NSCLC.
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Background
Lung cancer is the leading cause of cancer related deaths
in the world. Non-small cell lung cancer (NSCLC)
accounts for more than 85% of all cases of lung cancer,
and most patients with NSCLC have advanced disease at
diagnosis [1,2]. The therapies for lung cancer are mainly
based on traditional modes such as operation, chemo-
therapy and radiotherapy, however, the curative effect
obtained is less satisfactory. Recently, immunotherapy for
cancer has became the forth device following the tradi-
tional therapy. Antibody-based immunotherapy targeting
to tumor antigen or cell surface markers has achieved
some success for cancer including NSCLC, such as cetuxi-
mab, panitumumab, matuzumab and trastuzumab [3-9].
But only a few tumor-associated antigens or therapeutic
targets are available at present. Identifying novel antigens
(especially cellular membrane markers) will further
improve tumor immunotherapy.
In the past several years, considerable progress has been
made in the identification of tumor-associated antigens
recognized by monoclonal antibodies (mAbs) or autoan-
tibodies from the patients. The strategies such as serologi-
cal analysis of recombinant cDNA expression libraries
(SEREX), phage antibody library and ribosome display
have been used to screen and identify tumor antigens.
Besides, hybridoma technology can be taken as an availa-
ble tool to produce anti-tumor antibodies and identify
novel tumor antigens [10]. More than 1,000 tumor-asso-
ciated antigens have been reported so far. The importance
of these tumor antigens lies in their diagnostic and poten-
tial therapeutic utility. Moreover, those tumor antigens
can also provide some prognostic information for the can-
cer patients.
In the present study, we produced a monoclonal antibody
4E7 (McAb4E7) specific against human lung adencarci-
noma A549 cell line, which could inhibit proliferation of
A549 cells. Then, by proteomic technologies, we identi-
fied ATP synthase beta subunit (ATPB) to be the corre-
sponding antigen of McAb4E7. Immunohistochemstry
showed that the antigen of McAb4E7 mainly aberrantly
expressed in tumor cellular membrane in non-small cell
lung cancer (NSCLC), but not in small cell lung cancer
(SCLC). Our results suggested that abnormally expressed
ATPB on cell surface might be a potential tumor associ-
ated antigen in the immunodiagnostics and immuno-
therapy for NSCLC.
Methods
Materials
Human lung adencarcinoma cell line A549, human small
cell lung cancer cell line H-128 and human lung diploid
cell line MRC-5 were bought from American Type Culture
Collection (ATCC). Cells above were cultured in DMEM
or RPMI1640 (Gibco) medium, with 1% penicillin-strep-
tomycin and 10% fetal calf serum at 37°C in a 5% CO2-
humidified atmosphere. Pinpoint cell surface protein iso-
lation kit (Pierce Biotechnology, USA). Immobiline Dry-
Strips (17 cm, PI 3–10 NL), IPG buffer, Dry-Strip cover
fluid, urea, thiourea, ammonium bicarbonate were pur-
chased from BioRad (Hercules, CA, USA). DTT, TFA, CAN,
iodoacetamide, CHAPS, glycerol, agarose, ammonium
persulfate, glycine, acrylamide, Bis, TEMED, SDS, Tris
base, MTT, DMSO and CBB R-250 were obtained from
Sigma Chemical (St. Louis, MO, USA). Other chemicals
were domestic products.
Production of McAb4E7
Membrane proteins of A549 cells were isolated with the
pinpoint cell surface protein isolation kit according to the
manual instructions. Six to eight weeks old female BALB/
c mice were immunized each with 100 μg membrane pro-
teins of A549 cells mixed with Freund's complete adjuvant
(Sigma Chemical Co, St. Louis, Mo.) subcutaneously, and
boosted each with 100 μg proteins mixed with Freund's
incomplete adjuvant after 14, 21, 28 days respectively.
The valences of antibodies in peripheral blood were deter-
mined by ELISA. Three days after the last boosting, sensi-
tized spleen cells (5 × 108 cells) were harvested, mixed
with 1 × 108 NS-1 myeloma cells, and fused in 50% poly-
ethylene glycol 1500 with the proportion of 8:1. The fused
cells were distributed in 96-well plates (6 × 105/well) and
cultured for two weeks in RPMI 1640 with 10% fetal calf
serum containing hypoxanthine, aminopterin, and thy-
midine to select positive hybrid cells. The positive hybrid-
oma cells were subcloned by limiting dilution. Then 10–
12 weeks old female BALB/c mouse was inoculated with 3
× 106 hybridoma cells. The antibodies were further puri-
fied from the ascites via Protein-A affinity chromatogra-
phy. One of the antibodies with high valence against
A549 cells was named as McAb4E7. The antibody-sub-
class of McAb4E7 was determined by ELISA method.
MTT cell proliferation assay
A549 cells were seeded in 96-well plate at 6,000 cells per
well. 10 μg/mL and 80 μg/mL of mouse control IgG and
McAb4E7 antibody were added respectively. After 24 h, 48
h and 72 h, 20 μL MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) solution (5 mg/ml) was
added to each well and incubated at 37°C for a further 4
h. Then 200 μL of dimethylsulfoxide (DMSO) was added
to each well after the medium was removed. The optical
density (OD) values were measured at 490 nm on a scan-
ning multi-well spectrophotometer (BioRad Model 550,
USA). Compared with the control group, the relative sur-
vival rate of remained cells at each antibody concentration
was calculated from the absorbance values. The results
were analyzed by ANOVA and Student-Newman-Keuls
tests, the value of statistical significance being set at the p
< 0.05 level.BMC Cancer 2009, 9:16 http://www.biomedcentral.com/1471-2407/9/16
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Western blot
The cells were cracked by the RIPA lysis buffer (50 mM
Tris-HCl (pH 7.4), 1%NP-40, 0.25%Na-deoxycholate,
150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 mg/ml Apro-
tinin, 1 mM Na3VO4, 1 mM NaF). Then proteins were sus-
pended in Lammli sample buffer and centrifuged at 15,
000 rpm for 30 min. The supernatant was collected. Ten
μg of each protein sample was loaded per well and sepa-
rated with 12.5% SDS-PAGE. The proteins in gel were
electroblotted onto PVDF membranes (Millipore) by wet
blotting. After incubation in blocking buffer (1 × TBS,
0.1% Tween-20, and 5% w/v dry nonfat milk) for 1 h at
room temperature, membranes were incubated in a
1:1000 dilution of McAb4E7. Then the membrane was
incubated in a 1:10000 dilution of a HRP-conjugated
goat-anti-mouse IgG and a HRP-conjugated anti-GAPDH
antibody to confirm equal protein loading in each lane
(Zhongshan Biological, Beijing, China) for 45 min at
room temperature. Band containing targeting antigen was
detected using an ECL detection system (Western Light-
ing™, PerkinElmer Life Science, Boston, MA) and exposed
to X-ray film.
For 2-DE/Western blot, immediately after the second
dimension run, proteins in the gel were transferred to
PVDF membrane according to the method as mentioned
above. The PVDF membrane was stained with coomassie
R-250 after transferring, then was destained with several
changes of 40% methanol, 10% acetic acid before incu-
bated with McAb4E7.
Flow cytometric assay
The cells were collected and washed twice with phosphate
buffered saline (PBS). Then, the cells were adjusted to a
concentration of 1 × 106 cells per mL, and incubated with
McAb4E7 for 30 min at 4°C at 1:300 dilution. After
washed three times with PBS, fluorescein-isothiocyanate
(FITC)-labeled goat anti-mouse IgG (Becton Dickinson)
in PBS was added and further incubated for 20 min at
4°C. Finally, the cells were washed again with PBS, and
the membrane antigen expression was analyzed with a
fluorescence-activated cell sorter (ESP Elite, Beckman
Coulter).
Immunohistochemistry
NSCLC tissues (n = 65), their adjacent nontumourous tis-
sues (n = 62) and SCLC tissues (n = 10) were obtained
from department of pathology in West China Hospital of
Sichuan University. NSCLC tissues included 32 lung ade-
nocarcinoma samples and 33 squamous carcinoma sam-
ples. Tissue sections were treated with 0.3% hydrogen
peroxidase for 5 min, followed by blocking for 30 min
with normal goat serum at room temperature. Antibody
4E7(1:1000) were applied to the blocked sections and
incubated overnight at 4°C. The sections were incubated
for 30 min at 37°C with HRP-labeled goat anti-mouse IgG
antibody(1:500), and positive signals were visualized by
development in diaminobenzidine tetrahydrochloride
(DAB) solution. The sections were viewed under an Olym-
pus Ax-70 DMC Ie CCD camera to a PC monitor. The dif-
ference between groups was analyzed by Chi-square test,
and the value of statistical significance was set at the p <
0.05 level.
Two-demensional electrophoresis (2-DE)
2 × 107 A549 cells were solubilized in 1 ml lysis solution
(8 M urea, 4% CHAPS, 2 mmol/L TBP, 0.2% ampholyte,
traces of bromophenol blue) at 4°C for 20 min. Insoluble
material was removed by centrifugation at 15000 rpm at
4°C for 30 min. Protein concentration was determined by
the method of Bradford. Samples were frozen at -70°C,
and thawed immediately before use. For 17 cm IPG Ready
Strips, 1 mg proteins were loaded. After rehydrating the
strips for 14 h, IEF was carried out for 1 h at 200 V, 1 h at
500 V and 1 h at 1000 V; then a gradient was applied from
1000 to 8000 for 1 h and finally at 8000 V for 8 h to reach
a total of 72 KVh at 20°C. Following IEF separation, gel
strips were incubated for 15 min in equilibration buffer
(50 mM Tris-HCl, pH 8.8, 6 M urea, 30% glycerol, 2%
SDS) with 10 mg/mL DTT, followed by 15 min in equili-
bration buffer with 25 mg/mL iodoacetamide. Then the
strips were loaded on 12.5% SDS-PAGE gel, and were
electrophoresised for 20 min at a constant current of 10
mA and then at 30 mA per gel until the bromophenol blue
reached the bottom of gels. Sebsquently, the gels were
stained with with coomassie R-250, and destained with
40% methanol, 10% acetic acid.
MALDI-TOF-MS/MS analysis and database search
The excised gel piece was destained at room temperature
in 50 mM NH4HCO3 buffer, pH 8.8, containing 50% ACN
for 1–2 h, and dehydrated with 100% ACN. The gel piece
was rehydrated in 10 μL trypsin solution (50 mM
NH4HCO3, pH 8.0, containing 12.5 μg/mL) for 1 h, fol-
lowed by addition of 10 μL 50 mM NH4HCO3 buffer to
the gel piece. After incubation at 37°C overnight, 0.5 μL
incubation buffer was mixed with 0.5 μL matrix solution
(CHCA, 2 mg/mL in 50% ACN, and 0.5% TFA) and pipet-
ted directly onto the stainless steel sample plate of the
mass spectrometer. The sample was analyzed by Q-TOF
Premier Mass Spectrometer (Waters Micromass, Milford,
MA, USA). Ionization was achieved by a nitrogen laser
(337 nm) and acquisitions were performed in a V mode.
Standard calibration peptides were applied to the MALDI
plate as external calibration of the instrument and internal
calibration using either trypsin autolysis ions or matrix
was applied post acquisition for accurate mass determina-
tion. These parent ions in the mass range from 700 to
3000 m/z were selected to produce MS/MS ion spectra by
CID. The collision voltage varied between 34 and 161 eV
depending on the mass of the precursor ion. The MS and
MS/MS data were acquired and processed using MassLynxBMC Cancer 2009, 9:16 http://www.biomedcentral.com/1471-2407/9/16
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4.1 software (Waters Micromass, Milford, MA, USA). In a
MALDI Survey scan, only one MS scan was performed.
PKL files were analyzed with a licensed copy of the MAS-
COT 2.0 program (MatrixScience Ltd, London) against
Swiss-Prot protein database with a peptide tolerance of
0.5 Da. Searching parameters were set as following:
enzyme, trypsin; allowance of up to one missed cleavage
peptide; the peptide mass tolerance,1.0 Da and the frag-
ment ion mass tolerance, 0.3 Da; fixed modification
parameter, carbamoylmethylation; variable modification
parameters, oxidation; auto hits allowed; results format as
peptide summary report. Proteins were identified on the
basis of two or more peptides whose ions scores both
exceeded the threshold, p < 0.05, which indicates identifi-
cation at the 95% confidence level for those matched pep-
tides.
Results
Production and characterization of McAb4E7
With immunizing BALB/c mice by membrane proteins of
A549 cells, fourteen monoclonal hybridoma cell lines
were obtained after several fusion experiments. By West-
ern blot analysis, we found that a monoclonal antibody
(McAb4E7) produced by hybridoma cell line 4E7 was spe-
cific against A549 cells but not against H-128 cell line and
MRC-5 cell line (Figure 1A). Flow cytometric analysis
showed that the localization of the antigen of McAb4E7
was in cellular membrane of A549 cells (Figure 1B). The
subclass of McAb4E7 was identified to be IgG1 by ELISA
analysis.
Inhibitory effect of McAb4E7 on A549 cells proliferation
The effect of McAb4E7 on the proliferation of A549 cells
was evaluated via MTT assay. Compared with the
untreated and control IgG treated cells, the relative inhib-
itory rate of 80 μg/mL McAb4E7 on A549 cells was 14.9%
and 28.3% respectively after 48 h and 72 h (P < 0.05) (Fig-
ure 2). The results indicated that McAb4E7 could inhibit
the proliferation of A549 cells in vitro.
Immunohistochemical analysis for the antigen of McAb4E7
To further investigate the expression of the antigen of
McAb4E7 in lung cancer tissues, we performed immuno-
histochemical analysis using paraffin-embedded tissue
specimens. The expression of the antigen of McAb4E7 was
obviously positive in the cellular membrane of lung ade-
nocarcinoma and squamous carcinoma tissues (Figure 3A
and 3B), while weak expression of the antigen of
McAb4E7 could be seen in the cytoplasm in the adjacent
nontumourous tissues of NSCLC (Figure 3C). The antigen
of McAb4E7 was not be found in the tissues of SCLC (Fig-
ure 3D). The rate of expressed antigen of McAb4E7 in the
cellular membrane in lung adenocarcinoma, squamous
carcinoma and adjacent nontumourous lung tissues was
71.88%, 66.67% and 25.81% respectively (Table 1). The
rate of membrane expressed antigen had significant differ-
ence between NSCLC tissues and their adjacent nontu-
mourous tissues (P < 0.05), and it had no statistical
difference between lung adenocarcinoma and squamous
carcinoma (P > 0.05).
Western bolt and flow cytometric analysis for the antigen of  McAb4E7 Figure 1
Western bolt and flow cytometric analysis for the 
antigen of McAb4E7. (A) Western bolt detection for the 
expression of the antigen of McAb4E7, lane1: H-128 cells; 
lane 2: A549 cells; lane 3: MRC-5 cells; GAPDH was used as 
reference, the expression of the antigen of McAb4E7 was 
found in A549 cells (B-D) Flow cytometry analysis for the 
localization of the targeting antigen, the localization of anti-
gen of McAb4E7 was in cellular membrane of A549 cells, but 
not in MRC-5 and H-128 cells.
Inhibitory effect of McAb4E7 on A549 cells Figure 2
Inhibitory effect of McAb4E7 on A549 cells. The rela-
tive inhibitory rate of 80 μg/mL McAb4E7 on cultured A549 
cells was 14.9% and 28.3% respectively after 48 h and 72 h (P 
< 0.05); the relative inhibitory rate of 80 μg/mL IgG antibody 
and 10 μg/mL McAb4E7 had no statistical difference (P > 
0.05).BMC Cancer 2009, 9:16 http://www.biomedcentral.com/1471-2407/9/16
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Identification of the antigen of McAb4E7 by 2-DE/Western 
blot and MALDI-TOF-MS/MS analysis
To recognize the targeting antigen of McAb4E7, 2-DE/
Western blot was performed with A549 cells. Preliminary
experiment with Immobiline Dry-Strips (7 cm, 3–10 NL)
indicated that the positive protein spot was located at PI 5
and MW 55 kDa in the gel. To improve the resolution, 17
cm gels (17 cm, 3–10 NL) were used, and a quarter of the
gel was subjected to Western blot in view of the PI and
MW of the corresponding antigen of McAb4E7 (Figure 4).
Subcellular localization of the antigen of McAb4E7 Figure 3
Subcellular localization of the antigen of McAb4E7. (A and B) The targeting antigen mainly located in the cellar mem-
brane both in lung adenocarcinoma and squamous carcinoma (C) A little expression of the targeting antigen could be seen in 
the cytoplasm in the adjacent nontumourous lung tissues (D) The targeting antigen was not be found in the SCLC tissues; Mag-
nifications: A-D × 40.
Table 1: Ectopic expressioned ATPB in the cellular membrane in lung cancer tissues
Pathological types Number of samples Ectopic localization of ATPB in the cellular membrane Rate (%)
NSCLC Adenocarcinoma 32 23 71.88
Squamous carcinoma 33 22 66.67
Adjacent nontumourous tissues of NSCLC 62 16 25.81
SCLC 10 0 0
The rate of ectopic expressed ATPB in the cellular membrane had significant difference between NSCLC tissues and their adjacent nontumourous 
tissues (P < 0.05); the rate of ectopic expressed ATPB had no statistical difference between lung adenocarcinoma and squamous carcinoma (P > 
0.05).BMC Cancer 2009, 9:16 http://www.biomedcentral.com/1471-2407/9/16
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Then, the protein spot, corresponding to those showing a
positive reaction with the antibody 4E7 in 2-DE/Western
blot, was excised from the gel (Figure 4A).
The excised gel piece was destained and trypsinized into
peptides for MS and MS/MS analysis. Mass spectra were
acquired with a Q-TOF Premier Mass Spectrometer (Fig-
ure 5). The MS/MS data, including the mass values, the
intensity and the charge of the precursor ions, were ana-
lyzed with a licensed copy of the Mascot 2.0 program
against SWISS-PROT protein database. The charged ion of
1439.76 m/z and its fragment ions revealed the peptide
sequence, R.VALTGLTVAEYFR.D, unique to ATPB (Figure
5A and 5B). The protein spot was identified as ATP syn-
thase beta subunit (ATPB). The score was 62 (P < 0.05)
(Figure 5C).
Discussion
In this study, we produced the monoclonal antibody 4E7
using membrane proteins of lung adenocarcinoma cells
A549 as the immunogen by hybridoma technology, and
demonstrated that this antibody could inhibit the prolif-
eration of A549 cells. Most importantly, we identified the
ectopic ATP synthase beta subunit (ATPB) in the cellular
membrane to be the target antigen of McAb4E7, which
indicated that ATPB might be a potential target for NSCLC
immunotherapy.
There are several strategies for the identification of tumor-
associated antigens, such as serological analysis of recom-
binant cDNA expression libraries (SEREX), phage anti-
body library, ribosome display and tumor special
antibody cloning. We performed the last strategy here.
Generally speaking, potential molecular targets for mAb-
mediated immunotherapy must be accessible to the anti-
bodies, it is to say that the antigens should be cell surface
proteins or soluble growth factors. For this reason, we
used the membrane proteins of A549 cells as the immu-
nogen in our hybridoma strategy. As expected, the anti-
body secreted from hybridoma clone 4E7, specifically
recognized the cell surface protein in A549 cells and
NSCLC tissues was obtained.
ATPB is a subunit of ATP synthases constitutively
expressed in the inner mitochondrial membrane in nor-
mal cells [11]. However, some researches have reported
the ectopic expression of ATP synthases in primary cul-
tured endothelial cells [12-16]. Colon carcinoma cells and
prostate carcinoma cells also expressed ATP synthase on
the cell surface [17-20]. In present study, we found that
the expression of ATPB was also ectopically located on the
cell surface and up-regulated in human lung adencarci-
noma cell line A549, as well as in NSCLC tissues. The rates
of ectopic expressed ATPB in the cellular membrane in
lung adenocarcinoma and squamous carcinoma were sig-
nificantly higher than their adjacent nontumourous lung
tissues. These findings indicated that the ectopic expres-
sion of ATPB would be a tumor-associated antigen of
NSCLC.
It was reported that angiostatin, kringle 1–5 (K1–5) of
plasminogen, McAb against ATPB and small molecular
inhibitors could bind to ATP synthase on the cell surface,
and inhibited endothelial cell proliferation, migration,
even triggered apoptosis [21-23]. In the present study, we
found that McAb4E7 also exhibited inhibitory effect on
the proliferation of A549 cells to some extent. ATP syn-
thase on the cell surface was more active at low extracellu-
lar pH, such as in the tumor microenvironment. So
ectopic ATPB might play important role in the tumor
growth and development, and would be a potential target
for NSCLC immunotherapy. However, the functions of
ATPB and McAb4E7 need to be further studied.
Currently, proteomic technologies have been imple-
mented in analysis for cells and tissues protein expression
on large scale [24]. After failing to capture of the antigen
of McAb4E7 with immunoprecipitate technology, we
employed 2-DE/Western blot approach to locate and rec-
ognize the positive protein spot responsed to McAb4E7.
Ultimately, ATPB was identified to be the corresponding
antigen of McAb4E7. So the proteomic technologies pro-
vide us a potent tool to identify tumor associated anti-
gens, especially for identifying cellular membrane
antigens [25,26].
Conclusion
In the present study, we identified ectopic localized ATPB
as the corresponding antigen of McAb4E7 with the pro-
teomic technologies. ATPB on the cell surface may be a
potential biomarker and therapeutic targets for the immu-
notherapy of NSCLC. In order to explore the function of
2-DE/Western blot analysis of the targeting antigen of  McAb4E7 Figure 4
2-DE/Western blot analysis of the targeting antigen 
of McAb4E7. (A) The quarter 2-DE map of A549 cells, 
black arrow indicated the targeting antigen (B) Western blot 
detection for the targeting protein spot recognized by 
McAb4E7.BMC Cancer 2009, 9:16 http://www.biomedcentral.com/1471-2407/9/16
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MALDI-TOF-MS and MS/MS analysis of the antigen of McAb4E7 Figure 5
MALDI-TOF-MS and MS/MS analysis of the antigen of McAb4E7. (A) Peptide mass fingerprinting (PMF) of the target-
ing protein recognized by McAb4E7. Black arrow in the image indicated the peak of ATPB (B) MS/MS spectrum of peak [M 
+2H]2+ at m/z 1439.77 from positive spot matched sequence RVALTGLTVAEYFRD of ATPB (C) Probability based mowse 
score.BMC Cancer 2009, 9:16 http://www.biomedcentral.com/1471-2407/9/16
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ectopic localized ATPB and McAb4E7, more work need to
be done to evaluate their clinical applicability and specif-
icity in ongoing study. Furthermore, the marriage of target
identification with antibody enhancement technologies
will ultimately be translated into new and improved ther-
apies for cancer patients.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
ZJL and QFS carried out the 2-DE/western-blot and
drafted the manuscript. QS and SSJ performed the flow
cytometric assay. WW, BK and GHZ carried out the immu-
nohistochemical and western-blot, as well as the statisti-
cal analysis. LTG and LJC performed MALDI-TOF MS
studies. ZYQ helped in drafting the manuscript. JLY, FL
and YQW participated in the design of the study. Among
them, JLY critically revised the manuscript and FL contrib-
uted to the supply of lung cancer tissues. All authors read
and approved the final manuscript.
Acknowledgements
We thank Sheng-Yong Yang and Heng-Yi Xiao for critically reviewing the 
manuscript. We thank Ming-Hai Tang for kindly providing technical help in 
MS. This study was supported by the National Natural Science Foundation 
of China (No. 30872742).
References
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer
statistics, 2008.  CA Cancer J Clin 2008, 58:71-96.
2. Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, Jemal
A, Ward E, Anderson RN, Edwards BK: Annual report to the
nation on the status of cancer, 1975–2000, featuring the uses
of surveillance data for cancer prevention and control.  J Natl
Cancer Inst 2003, 95:1276-1299.
3. Breedveld FC: Therapeutic monoclonal antibodies.  Lancet
2000, 355:735-740.
4. Rossi A, Bria E, Maione P, Palazzolo G, Falanga M, Gridelli C: The
role of cetuximab and other epidermal growth factor recep-
tor monoclonal antibodies in the treatment of advanced
non-small cell lung cancer.  Rev Recent Clin Trials 2008, 3:217-227.
5. Kollmannsberger C, Schittenhelm M, Honecker F, Tillner J, Weber D,
Oechsle K, Kanz L, Bokemeyer C: A phase I study of the human-
ized monoclonal anti-epidermal growth factor receptor
(EGFR) antibody EMD 72000 (matuzumab) in combination
with paclitaxel in patients with EGFR-positive advanced non-
small-cell lung cancer (NSCLC).  Ann Oncol 2006, 17:1007-1013.
6. Zinner RG, Glisson BS, Fossella FV, Pisters KM, Kies MS, Lee PM,
Massarelli E, Sabloff B, Fritsche HA Jr, Ro JY, Ordonez NG, Tran HT,
Yang Y, Smith TL, Mass RD, Herbst RS: Trastuzumab in combina-
tion with cisplatin and gemcitabine in patients with Her2-
overexpressing, untreated, advanced non-small cell lung
cancer: report of a phase II trial and findings regarding opti-
mal identification of patients with Her2-overexpressing dis-
ease.  Lung Cancer 2004, 44:99-110.
7. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis
JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA,
Holmgren E, Kabbinavar F: Randomized phase II trial comparing
bevacizumab plus carboplatin and paclitaxel with carbopla-
tin and paclitaxel alone in previously untreated locally
advanced or metastatic non-small-cell lung cancer.  J Clin
Oncol 2004, 22:2184-2191.
8. Mu XL, Li LY, Zhang XT, Wang SL, Wang MZ: Evaluation of safety
and efficacy of gefitinib ('iressa', zd1839) as monotherapy in
a series of Chinese patients with advanced non-small-cell
lung cancer: experience from a compassionate-use pro-
gramme.  BMC Cancer 2004, 4:51.
9. Copeman M: Prolonged response to first-line erlotinib for
advanced lung adenocarcinoma.  J Exp Clin Cancer Res 2008,
27:59.
10. Ning Y, Wang Y, Li Y, Hong Y, Peng D, Liu Y, Wang J, Hao W, Tian
X, Wu F, Dong W, Wang L, Wu Q, Liu X, Gao J, He F, Qian X, Sun
QH, Li M: An alternative strategy for high throughput gener-
ation and characterization of monoclonal antibodies against
human plasma proteins using fractionated native proteins as
immunogens.  Proteomics 2006, 6:438-448.
11. Boyer PD: The ATP synthase–a splendid molecular machine.
Annu Rev Biochem 1997, 66:717-749.
12. Moser TL, Kenan DJ, Ashley TA, Roy JA, Goodman MD, Misra UK,
Cheek DJ, Pizzo SV: Endothelial cell surface F1–F0 ATP syn-
thase is active in ATP synthesis and is inhibited by angiosta-
tin.  Proc Natl Acad Sci USA 2001, 98:6656-6661.
13. Arakaki N, Nagao T, Niki R, Toyofuku A, Tanaka H, Kuramoto Y,
Emoto Y, Shibata H, Magota K, Higuti T: Possible role of cell sur-
face H+ -ATP synthase in the extracellular ATP synthesis
and proliferation of human umbilical vein endothelial cells.
Mol Cancer Res 2003, 1:931-939.
14. Chi SL, Pizzo SV: Angiostatin is directly cytotoxic to tumor
cells at low extracellular pH: a mechanism dependent on cell
surface-associated ATP synthase.  Cancer Res 2006, 66:875-882.
15. Moser TL, Stack MS, Asplin I, Enghild JJ, Højrup P, Everitt L, Hubchak
S, Schnaper HW, Pizzo SV: Angiostatin binds ATP synthase on
the surface of human endothelial cells.  Proc Natl Acad Sci USA
1999, 96:2811-2816.
16. Zhao Y, Zhang W, Kho Y, Zhao Y: Proteomic analysis of integral
plasma membrane proteins.  Anal Chem 2004, 76:1817-1823.
17. Champagne E, Martinez LO, Collet X, Barbaras R: Ecto-F1Fo ATP
synthase/F1 ATPase: metabolic and immunological func-
tions.  Curr Opin Lipidol 2006, 17:279-284.
18. Chi SL, Pizzo SV: Cell surface F1Fo ATP synthase: a new para-
digm?  Ann Med 2006, 38:429-438.
19. Jung KH, Song SH, Paik JY, Koh BH, Choe YS, Lee EJ, Kim BT, Lee KH:
Direct targeting of tumor cell F(1)F(0) ATP-synthase by
radioiodine angiostatin in vitro and in vivo.  Cancer Biother Radi-
opharm 2007, 22:704-712.
20. Das B, Mondragon MO, Sadeghian M, Hatcher VB, Norin AJ: A novel
ligand in lymphocyte-mediated cytotoxicity: expression of
the beta subunit of H+ transporting ATP synthase on the
surface of tumor cell lines.  J Exp Med 1994, 180:273-281.
21. Veitonmäki N, Cao R, Wu LH, Moser TL, Li B, Pizzo SV, Zhivotovsky
B, Cao Y: Endothelial cell surface ATP synthase-triggered cas-
pase-apoptotic pathway is essential for k1-5-induced antian-
giogenesis.  Cancer Res 2004, 64:3679-3686.
22. Chi SL, Wahl ML, Mowery YM, Shan S, Mukhopadhyay S, Hilderbrand
SC, Kenan DJ, Lipes BD, Johnson CE, Marusich MF, Capaldi RA,
Dewhirst MW, Pizzo SV: Angiostatin-like activity of a mono-
clonal antibody to the catalytic subunit of F1F0 ATP syn-
thase.  Cancer Res 2007, 67:4716-4724.
23. Kenan DJ, Wahl ML: Ectopic localization of mitochondrial ATP
synthase: a target for anti-angiogenesis intervention?  J Bioen-
erg Biomembr 2005, 37:461-465.
24. Hanash SM, Madoz-Gurpide J, Misek DE: Identification of novel
targets for cancer therapy using expression proteomics.
Leukemia 2002, 16:478-485.
25. Gao J, Gao Y, Ju Y, Yang J, Wu Q, Zhang J, Du X, Wang Z, Song Y, Li
H, Luo X, Ren F, Li J, Chen Y, Wang L, Xu H, Liu X, Wang J, Zhang
Y, Cai Y, Cui Y, Qian X, He F, Li M, Sun QH: Proteomics-based
generation and characterization of monoclonal antibodies
against human liver mitochondrial proteins.  Proteomics 2006,
6:427-437.
26. Liu B, Huang L, Sihlbom C, Burlingame A, Marks JD: Towards pro-
teome-wide production of monoclonal antibody by phage
display.  J Mol Biol 2002, 315:1063-1073.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/9/16/prepub